[ A23-21] Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 21.09.2023
Project no.:
A23-21
Commission:
Commission awarded on 27.03.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adult men with metastatic hormone-sensitive prostate cancer
Result of dossier assessment:
Indication of major added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A23-81 | Darolutamide (prostate cancer) - Addendum to Commission A23-21 | Commission completed |
Federal Joint Committee (G-BA)
2023-09-21 A G-BA decision was published.